APP and Alzheimer disease: It has been reported that AD patients show reduced nuclear levels of Nrf2 in hippocampal neurons [16, 17]; NQO-1, HO-1, SOD1, glutathione synthetic enzymes, and Nrf2 levels in hippocampal neurons are reduced in APP/PS1 transgenic AD mice and 3xTG model of AD [18, 19]; several Nrf2 inducers alleviated cognitive defects in transgenic AD animal models showing anti-AD potency [20–23].